Supplement researchSourced from PubMed and NIH
NutriStack
Free iPhone appUpdated September 28, 2026

Supplement × Supplement·Evidence index

Lutein and Zeaxanthin: what the research found

PubMed indexes 5 records that name Lutein and Zeaxanthin together, either in the title or in an interaction, co-administration, or pharmacokinetic context. 3 further sources came from NutriStack’s own review rather than from that query, and are labelled as such. The key findings come first, in the authors’ own words, followed by every study with its design and PubMed link.

A summary of published research, not medical advice. A pharmacist can check any combination against your full list of medicines and supplements.

Key findings

What the studies concluded.

Reviews and human studies first. Each quote is the authors’ own conclusion about their study, not a NutriStack assessment, and a single study is not a consensus.

“Oral micronutrient supplementation slowed GA progression toward the central macula, likely by augmenting the natural phenomenon of foveal sparing.”

Keenan et al. · 2025 · Human study · details

“Supplementing LZ resulted in increased MPOD levels, along with increased serum levels of L, Z, and BDNF. These changes were associated with improved visual and cognitive performances and reduction in eye strain and eye fatigue in the children receiving LZ gummies. The investigational product was safe and well tolerated.”

Parekh et al. · 2024 · Human study · details

“Our data show that L, Z, & MZ supplementation results in decreased serum IL-1β, TNF-α, and OxLDL. This suggests that these carotenoids are acting systemically to attenuate oxidative lipid products and inflammation, thus reducing their contribution to atherosclerotic plaque formation.”

The research

8 studies naming Lutein and Zeaxanthin.

Hand-reviewed sources first, then papers naming both substances in the title, then human trials and systematic reviews.

Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28.

JAMA ophthalmology · 2022 · PMID 35653117

Multicenter StudyRandomized Controlled TrialResearch Support, N.I.H., Extramural

“Results of this long-term epidemiologic follow-up study of the AREDS2 cohort suggest that lutein/zeaxanthin was an appropriate replacement for beta carotene in AREDS2 supplements. Beta carotene usage nearly doubled the risk of lung cancer, whereas there was no statistically significant increased risk with lutein/zeaxanthin. When compared with beta carotene, lutein/zeaxanthin had a potential beneficial association with late AMD progression.”

Chew et al. · Authors' conclusion

Names both Lutein and Zeaxanthin in its title. Selected by hand during source review for Lutein and Zeaxanthin, rather than by the automated PubMed query.

Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial.

JAMA · 2013 · PMID 23644932

Multicenter StudyRandomized Controlled TrialResearch Support, N.I.H., ExtramuralResearch Support, N.I.H., Intramural

“Addition of lutein + zeaxanthin, DHA + EPA, or both to the AREDS formulation in primary analyses did not further reduce risk of progression to advanced AMD. However, because of potential increased incidence of lung cancer in former smokers, lutein + zeaxanthin could be an appropriate carotenoid substitute in the AREDS formulation.”

Authors' conclusion

Names both Lutein and Zeaxanthin in its title. Selected by hand during source review for Lutein and Zeaxanthin, rather than by the automated PubMed query.

Macular pigment in donor eyes with and without AMD: a case-control study.

Investigative ophthalmology & visual science · 2001 · PMID 11133874

Comparative StudyHuman subjects

“The results are consistent with a theoretical model that proposes an inverse association between risk of AMD and the amounts of L and Z in the retina. The results are inconsistent with a model that attributes a loss of L and Z in the retina to the destructive effects of AMD.”

Bone et al. · Authors' conclusion

Selected by hand during source review for Lutein and Zeaxanthin, rather than by the automated PubMed query. It covers one side of the pair; it is listed as background the reviewer relied on, not as a study of the combination.

Lutein and Zeaxanthin Supplementation Improves Dynamic Visual and Cognitive Performance in Children: A Randomized, Double-Blind, Parallel, Placebo-Controlled Study.

Advances in therapy · 2024 · PMID 38363462

Randomized Controlled Trial

“Supplementing LZ resulted in increased MPOD levels, along with increased serum levels of L, Z, and BDNF. These changes were associated with improved visual and cognitive performances and reduction in eye strain and eye fatigue in the children receiving LZ gummies. The investigational product was safe and well tolerated.”

Parekh et al. · Authors' conclusion

Names both Lutein and Zeaxanthin in its title.

Lutein, zeaxanthin, and meso-zeaxanthin supplementation attenuates inflammatory cytokines and markers of oxidative cardiovascular processes in humans.

Nutrition, metabolism, and cardiovascular diseases : NMCD · 2024 · PMID 38890092

Randomized Controlled Trial

“Our data show that L, Z, & MZ supplementation results in decreased serum IL-1β, TNF-α, and OxLDL. This suggests that these carotenoids are acting systemically to attenuate oxidative lipid products and inflammation, thus reducing their contribution to atherosclerotic plaque formation.”

Stringham et al. · Authors' conclusion

Names both Lutein and Zeaxanthin in its title.

The effects of lutein/ zeaxanthin (Lute-gen(®)) on eye health, eye strain, sleep quality, and attention in high electronic screen users: a randomized, double-blind, placebo-controlled study.

Frontiers in nutrition · 2025 · PMID 39963662

“The results from this study provide support for the beneficial effects of 6 months of lutein and zeaxanthin supplementation on regular users of electronic screens. Compared to the placebo, there were improvements in several ophthalmic examinations for dry eyes and visual health. However, these findings were not corroborated by group differences in the administered self-report measures.”

Lopresti et al. · Authors' conclusion

Names both Lutein and Zeaxanthin in its title.

Lutein and Zeaxanthin and Their Roles in Age-Related Macular Degeneration-Neurodegenerative Disease.

Nutrients · 2022 · PMID 35215476

ReviewHuman subjects

“It has been shown that supportive therapy with lutein and zeaxanthin can have a beneficial effect in delaying the progression of eye diseases such as age-related macular degeneration (AMD) and cataracts. This article presents the current state of knowledge on the role of lutein and zeaxanthin, especially from human studies targeting their metabolism and bioavailability, with recommendations to consume xanthophyll-rich foods.”

Mrowicka et al. · From the abstract

Names both Lutein and Zeaxanthin in its title.

Limitations

What this evidence cannot tell you.

Search-based evidence indexes have real limits, and it is worth being explicit about them:

How to read this page

A literature summary, not guidance.

NutriStack

Track what you actually take.

NutriStack is a free iPhone app for organising a supplement routine: what you take, when, and what the published record says about it. Its exploratory interaction checker covers Lutein, Zeaxanthin, and several hundred other substances.

Log your routine, get reminders at the times you choose, and scan a label to add a product. The checker is a research and organisation tool, not a clinical decision aid.

NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.